hit counter
Amyris, Inc. (AMRS) Stock News Sentiment & Price - Sentifly
AMRS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Amyris, Inc. (AMRS)

USA
Specialty Chemicals
NASDAQ
AMRS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AMRS Latest news
The Motley Fool
Negative
Why Shares of Amyris Are Plummeting This Week
2021-11-11 19:15

There's nothing artificial about the plunging price of this synthetic biology stock.

PRNewsWire
Neutral
Amyris Prices $600.0 Million Of 1.50% Convertible Senior Notes Due 2026
2021-11-10 08:00

EMERYVILLE, Calif., Nov. 10, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026 (the "notes").

The Motley Fool
Negative
Why Shares of Amyris Are Getting Crushed Today
2021-11-09 14:50

Bears are turning their backs on this synbio stock today.

Pulse2
Negative
Amyris (AMRS) Stock: Why The Price Substantially Fell Today
2021-11-09 13:23

The stock price of Amyris Inc (NASDAQ: AMRS) fell over 30% during intraday trading today. This is why it happened.

Seeking Alpha
Neutral
Amyris, Inc. (AMRS) CEO John Melo on Q3 2021 Results - Earnings Call Transcript
2021-11-08 22:53

Amyris, Inc. (AMRS) CEO John Melo on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Amyris, Inc. (AMRS) Reports Q3 Loss, Lags Revenue Estimates
2021-11-08 19:09

Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -80.00% and -25.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire
Neutral
Amyris To Offer $400.0 Million Of Convertible Senior Notes Due 2026
2021-11-08 16:35

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that it proposes to offer $400.0 million aggregate principal amount of convertible senior notes due 2026 (the "notes"), subject to market conditions and other factors.

PRNewsWire
Neutral
Amyris, Inc. Reports Third Quarter 2021 Financial Results
2021-11-08 16:11

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced financial results for its third quarter ended September 30, 2021.

Benzinga
Positive
Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine
2021-11-08 10:15

Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month.

Seeking Alpha
Neutral
Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition
2021-11-04 07:33

Amyris, a synthetic clean health and beauty biology company, is a key supplier of sustainable and natural ingredients and possesses some strong consumer brands too. Lack of market enthusiasm following the MG Empower deal points to investors having some doubts about financial capacity in view of the amount of cash in the balance sheet.

Loading more news...